The drug has the potential to change the treatment of individuals with its impressive 71.2-pound weight loss , restoring hope in patients with severe obesity who are usually intractable to diet, exercise, and existing medications because of record-setting weight loss, meaningful reduction in knee pain, and a new triple-hormone agent
At this time, limited published data confirm that GLP-1 patches work at therapeutic levels comparable to injectable formulations
Consider whether traveling is feasible
Here are some key findings: Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Northwestern Now posed five questions to the study senior author Dr
Twelve hours is well within the acceptable window for all weekly GLP-1 medications
Bring a copy of your medication list and pharmacy contact information to ensure hospital pharmacists have accurate information about your compounded formulations